Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Charles River 4Q Financial Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Charles River 4Q Financial Results

Acquisition of Explora BioLabs and robust performance in the DSA segment, contribute to fourth-quarter revenue growth.

By: Anthony Vecchione

Charles River
4Q Revenues: $1.10 billion (+21%)
4Q Earnings: $187.4 million (+36%)
FY Revenues: $3.98 billion (+12%)
FY Earnings: $492.6 million (+24%)

Comments: The addition of a 53rd week at the end of 2022, contributed approximately 5.8% to reported fourth-quarter revenue growth. The acquisition of Explora BioLabs contributed 1.8% to consolidated fourth-quarter revenue growth, and the divestitures of the Research Models and Services operations in Japan (RMS Japan) and the CDMO site in Sweden (CDMO Sweden) and the Avian Vaccine business reduced reported revenue growth by 0.5%.

Fourth quarter revenue for the Research Models and Services (RMS) segment was $196.1 million, an increase of 18%. The Explora BioLabs acquisition and the addition of the 53rd week contributed 10.1% and 4.5%, respectively, to RMS revenue growth in the quarter.

Revenue for the Discovery and Safety Assessment (DSA) segment was $691.7 million in the quarter, up 29.5%.

Fourth quarter revenue for the Manufacturing segment was $212.1 million, an increase of 3%.


 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters